EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploiting Vitamin D Receptor and Its Ligands to Target Squamous Cell Carcinomas of the Head and Neck

Laura Koll, Désirée Gül iD, Manal I Elnouaem, Hanaa Raslan, Omneya R Ramadan iD, Shirley K Knauer iD, Sebastian Strieth, Jan Hagemann, Roland H Stauber, Aya Khamis iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24054675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Laura Koll und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology Head and Neck Surgery, Molecular and Cellular Oncology, University Medical Center, 55131 Mainz, Germany. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Receptors, Calcitriol, Vitamin D, Vitamins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Academic Exchange Service, DAAD/TransMed, DFG projects, Wegener Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitamin D (VitD) and its receptor (VDR) have been intensively investigated in many cancers. As knowledge for head and neck cancer (HNC) is limited, we investigated the (pre)clinical and therapeutic relevance of the VDR/VitD-axis. We found that VDR was differentially expressed in HNC tumors, correlating to the patients’ clinical parameters. Poorly differentiated tumors showed high VDR and Ki67 expression, whereas the VDR and Ki67 levels decreased from moderate to well-differentiated tumors. The VitD serum levels were lowest in patients with poorly differentiated cancers (4.1 ± 0.5 ng/mL), increasing from moderate (7.3 ± 4.3 ng/mL) to well-differentiated (13.2 ± 3.4 ng/mL) tumors. Notably, females showed higher VitD insufficiency compared to males, correlating with poor differentiation of the tumor. To mechanistically uncover VDR/VitD’s pathophysiological relevance, we demonstrated that VitD induced VDR nuclear-translocation (VitD < 100 nM) in HNC cells. RNA sequencing and heat map analysis showed that various nuclear receptors were differentially expressed in cisplatin-resistant versus sensitive HNC cells including VDR and the VDR interaction partner retinoic acid receptor (RXR). However, RXR expression was not significantly correlated with the clinical parameters, and cotreatment with its ligand, retinoic acid, did not enhance the killing by cisplatin. Moreover, the Chou–Talalay algorithm uncovered that VitD/cisplatin combinations synergistically killed tumor cells (VitD < 100 nM) and also inhibited the PI3K/Akt/mTOR pathway. Importantly, these findings were confirmed in 3D-tumor-spheroid models mimicking the patients’ tumor microarchitecture. Here, VitD already affected the 3D-tumor-spheroid formation, which was not seen in the 2D-cultures. We conclude that novel VDR/VitD-targeted drug combinations and nuclear receptors should also be intensely explored for HNC. Gender-specific VDR/VitD-effects may be correlated to socioeconomic differences and need to be considered during VitD (supplementation)-therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellReceptors, CalcitriolVitamin DVitaminsHead and Neck NeoplasmsMolecular Targeted TherapyFemaleHumansMaleCisplatinKi-67 AntigenLigandsPhosphatidylinositol 3-Kinases

Stichwörter der Autor:innen

3D tumor spheroidscalcitriolgender-specific effectsnuclear receptors

Substanzen

CisplatinKi-67 AntigenLigandsPhosphatidylinositol 3-KinasesReceptors, CalcitriolVitamin DVitamins

Autor:innen und Institutionen

  • Department of Otorhinolaryngology Head and Neck Surgery, Molecular and Cellular Oncology, University Medical Center, 55131 Mainz, Germany.
  • Oral Pathology Department, Faculty of Dentistry, Alexandria University, Alexandria 5372066, Egypt.
  • Centre for Medical Biotechnology (ZMB/CENIDE), Institute for Molecular Biology, University Duisburg-Essen, Universitätsstraße, 45117 Essen, Germany.
  • Department of Otorhinolaryngology, University Medical Center Bonn, 53127 Bonn, Germany.

ORCID-Profile: Désirée Gül, Omneya R Ramadan, Shirley K Knauer, Aya Khamis

Förderung

  • German Academic Exchange Service
  • DAAD/TransMed, DFG projects
  • Wegener Stiftung
  • University Hospital Mainz

Zitieren

APA

Koll, L., Gül, D., Elnouaem, M. I., Raslan, H., Ramadan, O. R., Knauer, S. K., Strieth, S., Hagemann, J., Stauber, R. H., & Khamis, A. (2023). Exploiting Vitamin D Receptor and Its Ligands to Target Squamous Cell Carcinomas of the Head and Neck. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054675

Vancouver

Koll L, Gül D, Elnouaem MI, Raslan H, Ramadan OR, Knauer SK, et al. Exploiting Vitamin D Receptor and Its Ligands to Target Squamous Cell Carcinomas of the Head and Neck. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054675

BibTeX
@article{Koll2023,
  author = {Koll, Laura and Gül, Désirée and Elnouaem, Manal I and Raslan, Hanaa and Ramadan, Omneya R and Knauer, Shirley K and Strieth, Sebastian and Hagemann, Jan and Stauber, Roland H and Khamis, Aya},
  title = {Exploiting Vitamin D Receptor and Its Ligands to Target Squamous Cell Carcinomas of the Head and Neck},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24054675}
}
Kostenlos starten →